Fanconi Anemia Complementary Group A (FANCA) Facilitates the Occurrence and Progression of Liver Hepatocellular Carcinoma.
Biomarker
FANCA
Immunity
LIHC
Prognosis
Journal
Digestive diseases and sciences
ISSN: 1573-2568
Titre abrégé: Dig Dis Sci
Pays: United States
ID NLM: 7902782
Informations de publication
Date de publication:
28 Jan 2024
28 Jan 2024
Historique:
received:
04
09
2023
accepted:
02
01
2024
medline:
29
1
2024
pubmed:
29
1
2024
entrez:
28
1
2024
Statut:
aheadofprint
Résumé
Liver hepatocellular carcinoma (LIHC) is a serious liver disease worldwide, and its pathogenesis is complicated. This study investigated the potential role of FANCA in the advancement and prognosis of LIHC. Public databases, quantitative reverse transcription polymerase chain reaction (qRT-PCR), western blot (WB) and immunohistochemistry (IHC) were employed to measure FANCA expression between tumor and normal samples. The relationship between FANCA expression and prognosis of LIHC patients were examined. Functional enrichment of FANCA-related genes was performed. Furthermore, univariate and multivariate analyses were conducted to determine the independent prognosis value of FANCA in LIHC. Finally, influence of FANCA knockout on the proliferation, migration, and invasion of HepG2 cell was validated with cloning formation, CCK8, and Transwell assays. Expression analysis presented that FANCA had high expression level in LIHC tissues and cells. Receiver operating characteristic (ROC) curve analysis showed that FANCA was of great diagnosis value in LIHC. Clinicopathological analysis revealed that FANCA was significantly greater expressed in the advanced stage than in the early stage of LIHC. Univariate, multivariate, and Kaplan-Meier survival analysis confirmed that high expression of FANCA was strongly associated with poor survival of LIHC patients. In addition, high level of FANCA in LIHC showed a negative association with immunoinfiltrated B cells, T cells, and stromal scores. Moreover, Knockout of FANCA significantly inhibited HepG2 cell proliferative activity, migration, and invasion ability. Our data revealed that high level of FANCA was closely associated with LIHC malignant progression, suggesting its potential utility as a diagnostic, predictive indicator, and therapeutic target.
Sections du résumé
BACKGROUND
BACKGROUND
Liver hepatocellular carcinoma (LIHC) is a serious liver disease worldwide, and its pathogenesis is complicated.
AIMS
OBJECTIVE
This study investigated the potential role of FANCA in the advancement and prognosis of LIHC.
METHODS
METHODS
Public databases, quantitative reverse transcription polymerase chain reaction (qRT-PCR), western blot (WB) and immunohistochemistry (IHC) were employed to measure FANCA expression between tumor and normal samples. The relationship between FANCA expression and prognosis of LIHC patients were examined. Functional enrichment of FANCA-related genes was performed. Furthermore, univariate and multivariate analyses were conducted to determine the independent prognosis value of FANCA in LIHC. Finally, influence of FANCA knockout on the proliferation, migration, and invasion of HepG2 cell was validated with cloning formation, CCK8, and Transwell assays.
RESULTS
RESULTS
Expression analysis presented that FANCA had high expression level in LIHC tissues and cells. Receiver operating characteristic (ROC) curve analysis showed that FANCA was of great diagnosis value in LIHC. Clinicopathological analysis revealed that FANCA was significantly greater expressed in the advanced stage than in the early stage of LIHC. Univariate, multivariate, and Kaplan-Meier survival analysis confirmed that high expression of FANCA was strongly associated with poor survival of LIHC patients. In addition, high level of FANCA in LIHC showed a negative association with immunoinfiltrated B cells, T cells, and stromal scores. Moreover, Knockout of FANCA significantly inhibited HepG2 cell proliferative activity, migration, and invasion ability.
CONCLUSIONS
CONCLUSIONS
Our data revealed that high level of FANCA was closely associated with LIHC malignant progression, suggesting its potential utility as a diagnostic, predictive indicator, and therapeutic target.
Identifiants
pubmed: 38282187
doi: 10.1007/s10620-024-08282-3
pii: 10.1007/s10620-024-08282-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Middle-Aged and Young Teachers' Basic Ability Promotion Project of Guangxi
ID : Grant No. 2022KY0542
Organisme : Middle-Aged and Young Teachers' Basic Ability Promotion Project of Guangxi
ID : Grant No. 2022KY0532
Organisme : Fundación para el Fomento en Asturias de la Investigación Científica Aplicada y la Tecnología
ID : Grant No. 20212348
Organisme : Baise Scientific Research and Technology Development Plan in 2021
ID : Grant No. 20212347
Organisme : Youjiang Medical University for Nationalities Scientific Research Project
ID : Grant No. yy2020gcky040
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Marengo A, Rosso C, Bugianesi E. Liver cancer: connections with obesity, fatty liver, and cirrhosis. Annu Rev Med 2016;67:103–117.
doi: 10.1146/annurev-med-090514-013832
pubmed: 26473416
Rumgay H, Arnold M, Ferlay J et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol 2022;6:1598–1606.
doi: 10.1016/j.jhep.2022.08.021
Heimbach JK, Kulik LM, Finn RS et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018;1:358–380.
doi: 10.1002/hep.29086
Li L, Chen J, Xu W, Ding X, Wang X, Liang J. Clinical characteristics of hepatocellular carcinoma patients with normal serum alpha-fetoprotein level: a study of 112 consecutive cases. Asia Pac J Clin Oncol 2018;5:e336–e340.
Turshudzhyan A, Wu GY. Persistently rising alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: a review. J Clin Transl Hepatol 2022;1:159–163.
doi: 10.14218/JCTH.2021.00176
Del VJ, Rofes P, Moreno-Cabrera JM et al. Exploring the role of mutations in Fanconi anemia genes in hereditary cancer patients. Cancers (Basel). 2020;12:829.
doi: 10.3390/cancers12040829
Boussios S, Rassy E, Moschetta M et al. BRCA mutations in ovarian and prostate cancer: bench to bedside. Cancers (Basel). 2022;14:3888.
doi: 10.3390/cancers14163888
pubmed: 36010882
pmcid: 9405840
Morgan NV, Tipping AJ, Joenje H, Mathew CG. High frequency of large intragenic deletions in the Fanconi anemia group a gene. Am J Hum Genet 1999;5:1330–1341.
doi: 10.1086/302627
Garcia-Higuera I, Taniguchi T, Ganesan S et al. Interaction of the Fanconi anemia proteins and Brca1 in a common pathway. Mol Cell 2001;2:249–262.
doi: 10.1016/S1097-2765(01)00173-3
Pan Y, Yang X, Zhang F et al. A heterozygous hypomorphic mutation of FANCA causes impaired follicle development and subfertility in female mice. Mol Genet Genomics 2021;1:103–112.
doi: 10.1007/s00438-020-01730-5
Peake JD, Noguchi E. Fanconi anemia: current insights regarding epidemiology, cancer, and DNA repair. Hum Genet 2022;12:1811–1836.
doi: 10.1007/s00439-022-02462-9
Nalepa G, Clapp DW. Fanconi anaemia and cancer: an intricate relationship. Nat Rev Cancer 2018;3:168–185.
doi: 10.1038/nrc.2017.116
Rafnar T, Gudbjartsson DF, Sulem P et al. Mutations in Brip1 confer high risk of ovarian cancer. Nat Genet 2011;11:1104–1117.
doi: 10.1038/ng.955
Szklarczyk D, Kirsch R, Koutrouli M et al. The STRING Database in 2023: protein–protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res 2023;D1:D638–D646.
doi: 10.1093/nar/gkac1000
Li Y, Liu X, Chen H et al. Bioinformatics analysis for the role of Calr in human cancers. PLoS ONE 2021;12:e261254.
Okada M, Shi YB. Cell Proliferation analysis during Xenopus metamorphosis: using 5-ethynyl-2-deoxyuridine (Edu) to stain proliferating intestinal cells. Cold Spring Harb Protoc 2017;9:t97717.
Raeeszadeh-Sarmazdeh M, Do LD, Hritz BG. Metalloproteinases and their inhibitors: potential for the development of new therapeutics. Cells-Basel 2020;9:1313.
doi: 10.3390/cells9051313
Dufour C, Pierri F. Modern management of Fanconi anemia. Hematol Am Soc Hematol Educ Program 2022;1:649–657.
doi: 10.1182/hematology.2022000393
Savage SA, Dufour C. Classical inherited bone marrow failure syndromes with high risk for myelodysplastic syndrome and acute myelogenous leukemia. Semin Hematol 2017;2:105–114.
doi: 10.1053/j.seminhematol.2017.04.004
Moreno OM, Paredes AC, Suarez-Obando F, Rojas A. An update on Fanconi anemia: clinical, cytogenetic and molecular approaches (review). Biomed Rep 2021;3:74.
doi: 10.3892/br.2021.1450
Altintas B, Giri N, McReynolds LJ, Best A, Alter BP. Genotype–phenotype and outcome associations in patients with Fanconi anemia: the National Cancer Institute cohort. Haematologica 2023;1:69–82.
Danovi S. Fanconi anemia-associated signature in cancer. Nat Genet 2023;1:1.
doi: 10.1038/s41588-022-01292-9
Chan KK, Abdul-Sater Z, Sheth A et al. Sik2 kinase synthetic lethality is driven by spindle assembly defects in FANCA-deficient cells. Mol Oncol 2022;4:860–884.
doi: 10.1002/1878-0261.13027
Salemme V, Centonze G, Cavallo F, Defilippi P, Conti L. The crosstalk between tumor cells and the immune microenvironment in breast cancer: implications for immunotherapy. Front Oncol 2021;11:610303.
doi: 10.3389/fonc.2021.610303
pubmed: 33777750
pmcid: 7991834
Li J, Li X, Zhang C, Zhang C, Wang H. A signature of tumor immune microenvironment genes associated with the prognosis of non-small cell lung cancer. Oncol Rep 2020;3:795–806.
Sun J, Zhang Z, Bao S et al. Identification of tumor immune infiltration-associated LNCRNAs for improving prognosis and immunotherapy response of patients with non-small cell lung cancer. J Immunother Cancer 2020;8:e000110.
doi: 10.1136/jitc-2019-000110
pubmed: 32041817
pmcid: 7057423
Milletti G, Strocchio L, Pagliara D et al. Canonical and noncanonical roles of Fanconi anemia proteins: implications in cancer predisposition. Cancers (Basel) 2020;12:2684.
doi: 10.3390/cancers12092684
pubmed: 32962238
Ge PL, Li SF, Wang WW et al. Prognostic values of immune scores and immune microenvironment-related genes for hepatocellular carcinoma. Aging (Albany NY) 2020;6:5479–5499.
doi: 10.18632/aging.102971
Wang H, Wu X, Chen Y. Stromal-immune score-based gene signature: a prognosis stratification tool in gastric cancer. Front Oncol 2019;9:1212.
doi: 10.3389/fonc.2019.01212
pubmed: 31781506
pmcid: 6861210
Xing Z, Chu C, Chen L, Kong X. The use of gene ontology terms and KEGG pathways for analysis and prediction of oncogenes. Biochim Biophys Acta 2016;11:2725–2734.
doi: 10.1016/j.bbagen.2016.01.012
Li H, Lu S, Chen Y et al. Akt2 phosphorylation of Hexokinase 2 at T473 promotes tumorigenesis and metastasis in colon cancer cells via Nf-Kappab, Hif1Alpha, Mmp2, and Mmp9 upregulation. Cell Signal 2019;58:99–110.
doi: 10.1016/j.cellsig.2019.03.011
pubmed: 30877036
Zhao Y, Hu F, Wang Q. Cortactin contributes to the tumorigenesis of gastric cancer by activating Erk/Mmp pathway. Heliyon 2023;7:e18289.
doi: 10.1016/j.heliyon.2023.e18289
Cao ZQ, Wang Z, Leng P. Aberrant N-cadherin expression in cancer. Biomed Pharmacother 2019;118:109320.
doi: 10.1016/j.biopha.2019.109320
pubmed: 31545265
Liao S, Yu C, Liu H, Zhang C, Li Y, Zhong X. Long non-coding RNA H19 promotes the proliferation and invasion of lung cancer cells and regulates the expression of E-cadherin, N-cadherin, and vimentin. Onco Targets Ther. 2019;12:4099–4107.
doi: 10.2147/OTT.S185156
pubmed: 31190899
pmcid: 6535668
Song Y, Ye M, Zhou J, Wang Z, Zhu X. Targeting E-cadherin expression with small molecules for digestive cancer treatment. Am J Transl Res 2019;7:3932–3944.